Certara, Inc. (CERT)

Certara's stock price decreased by 34.40% over the past six months, with a closing price of $7.38 as of February 5, 2026. In Q3 2025, the company reported an EPS of $0.11 and revenue of $104.6 million, a 10% year-over-year increase, but the stock price fell by 2.59% in after-hours trading. Other events include the Chemaxon acquisition, the launch of Certara IQ, a $41 million stock repurchase, and a repriced term loan.

Specific demand seasonality information for Certara, Inc.'s products and services was not explicitly detailed in the provided search results.

Certara, Inc. is a global leader in biosimulation software and technology-enabled services, crucial for pharmaceutical, biotechnology, and medical device developers. The company operates in the Technology Services sector, providing a suite of software products and services, including biosimulation software like Simcyp and Phoenix WinNonlin, as well as platforms like Certara IQ, D360, Pinnacle 21, GlobalSubmit eCTD Software, Certara.AI, and Value Communication Software. Certara's services cover cell and gene therapy, clinical pharmacology, complex biologics, decision analytics, drug development, regulatory strategy, and model-based analysis.

Certara has a significant global presence, serving customers in over 70 countries across the Americas, EMEA, and Asia Pacific regions. Its operations extend to countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia.

Certara maintains a strong brand reputation as a global leader in biosimulation, trusted by regulatory agencies. Its customers have been associated with 90% or more of all novel drug approvals by the FDA from 2014 through 2024. The company is considered a "knowledge powerhouse" in drug development, employing over 350 scientific consultants and industry experts. Analyst sentiment is generally positive, with a consensus rating of "Moderate Buy". However, recent scrutiny regarding financial performance is indicated by a news headline mentioning "Certara's (NASDAQ:CERT) Returns On Capital Not Reflecting Well On The Business."

Certara, Inc. has substantial institutional ownership, with 458 institutional owners and shareholders holding 170,440,422 shares. Major institutional owners include Wasatch Advisors Inc, BlackRock, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, ArrowMark Colorado Holdings LLC, Deerfield Management Company, L.p. (series C), iShares Core S&P Small-Cap ETF (IJR), Geneva Capital Management Llc, WGROX - Wasatch Core Growth Fund Investor Class shares, and Teacher Retirement System Of Texas. Institutional investors and hedge funds collectively own 73.96% of the stock. Individual insiders, such as William Feehery, have also purchased shares.